Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

TRAIL receptor-binding agents and uses of same

A use and antibody technology, applied in the direction of antibodies, applications, drug combinations, etc., can solve the problems of limited clinical application value and toxic side effects of TNF-α and Fas

Active Publication Date: 2017-08-29
BEIJING SINOTAU BIO PHARMA TECH CO LTD
View PDF154 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, TNF-α and Fas have limited clinical application value due to their toxic side effects

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • TRAIL receptor-binding agents and uses of same
  • TRAIL receptor-binding agents and uses of same
  • TRAIL receptor-binding agents and uses of same

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0177] Preparation of polyclonal antisera and immunogens. Methods of producing antibodies or antibody fragments of the present technology generally involve immunizing a subject (typically a non-human subject such as a mouse or rabbit) with a purified TRAIL receptor polypeptide or with cells expressing a TRAIL receptor polypeptide. Any immunogenic portion of a TRAIL receptor polypeptide can be employed as an immunogen. Suitable immunogenic preparations may contain, for example, recombinantly expressed TRAIL receptor polypeptides or chemically synthesized TRAIL receptor polypeptides. Standard techniques for polyclonal and monoclonal antibody preparation can be used to generate TRAIL receptor binding agents that bind to a TRAIL receptor polypeptide or a portion or fragment thereof using the isolated TRAIL receptor polypeptide or a portion or fragment thereof as an immunogen. Full length TRAIL receptor polypeptides may be used, or alternatively, the present technology provides fo...

Embodiment 1

[0320] Example 1 Characterization of Binding Specificity and Affinity of HUCTB006

[0321] 1.1 Binding specificity

[0322] The binding specificity of HuCTB006 was assessed by chemiluminescent enzyme immunoassay (CLEIA). DR4-His–EC (batch number: 090222-P, 0.72mg / mL, Escherichia coli), DcR1-His (recombinant human TRAIL R3 / TNFRSF10C, Novoprotein Science, batch number: 0328670), DcR2-His (recombinant human TRAIL R4 / TNFRSF10d , Sino Biological, batch number LC06JU1502) and OPG-His (recombinant human osteoprotegerin (recombinant human osteoprotegerin) / TNFRSF11B, Wuxi Pharmatech Co.Ltd, batch number: 20120717) were coated on the microplate, and then it was blocked (Blocked).

[0323] HuCTB006 was diluted to 200, 40 and 8 ng / mL and added to the wells. After incubation for 1 hour at 37, the plates were washed. The binding of HuCTB006 to the immobilized antigen was detected with HRP-labeled secondary antibody and substrate solution. The result shows, as figure 1 As shown, there w...

Embodiment 2

[0326] Example 2 In vitro effectiveness of HuCTB006 treatment

[0327] 2.1 Cytotoxicity of HuCTB006 in human normal tissue cell lines

[0328] Several human normal tissue cell lines, including human lung epithelial fibroblast WI-38, human embryonic lung fibroblast HFL-1, human umbilical vein epithelial cell HUV-EC-C, and human hepatic differentiated cells derived from liver-induced cells (Acquired from Peking University Third Hospital). Cells at 37 °C and 5% CO 2 and culture medium containing 10% FBS. The medium of WI-38 was MEM, and the medium of HFL-1 and HUV-EC-C was F-12K. Cells were treated with oxaliplatin for 24 hours, and then different concentrations of CTB006 were added to the combination group. Results were determined 24 hours after treatment, as image 3 and Figure 4 shown. The examined human normal tissue cells were not sensitive to CTB006, indicating that HuCTB006 had no cytotoxicity to human normal tissue cells.

[0329] 2.2 Cytotoxicity of CTB006 in hu...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention discloses TRAIL receptor-binding agents, and their therapeutic effects on tumor inhibition in vitro and in vivo, alone or in combination with various chemotherapeutic agents. In particular, the present invention discloses methods for the treatment of cancer, comprising administrating a TRAIL receptor binding agent of the present technology, alone or in combination with a chemotherapeutic agent.

Description

field of invention [0001] The present disclosure generally relates to therapeutic uses of TRAIL receptor binding agents. In particular, the present disclosure relates to methods and compositions including CTB006, an anti-TRAIL-R2 (DR5) antibody, and its therapeutic effects in vitro and in vivo for tumor suppression alone or in combination with various chemotherapeutic agents. Background of the invention [0002] TRAIL was identified in the 1990s and is known to play an important role in the immune surveillance of tumor cells. Activated T lymphocytes and NK cells express high levels of TRAIL, which endows these immunocompetent cells with the ability to kill tumor cells. Animal studies have shown that knockout of TRAIL leads to increased tumor incidence with age. Therefore, TRAIL deficiency or underexpression may be a factor in tumorigenesis. [0003] Shortly after TRAIL was discovered, attention was paid to its potential as an anticancer agent for cancer treatment. This i...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07K16/28C12N15/13C12N5/20C12N15/63C12P21/08A61K39/395
CPCA61K39/395A61K39/39558C07K16/2878A61K2039/505C07K2317/33C07K2317/73C07K2317/92A61P35/00A61K2300/00G01N33/574
Inventor 沈恩允李哲赵家根
Owner BEIJING SINOTAU BIO PHARMA TECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com